About Skyepharma
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs)
- Headquarter London, United Kingdom
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$38.7 M (USD), Debt – Conventional
May 12, 2015
-
Investors
Barclays
& 1 more
-
Employee Count
Employee Count
-
Acquired by
& 1 more
(Jun 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Skyepharma
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $38.7M
-
First Round
First Round
(27 Dec 2006)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2015 | Amount | Debt – Conventional - Skyepharma | Valuation |
investors |
|
| Mar, 2014 | Amount | Post-IPO - Skyepharma | Valuation |
investors |
|
| Dec, 2006 | Amount | Debt – Conventional - Skyepharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Skyepharma
Skyepharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Barclays and Phillips Medisize. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified financial services are provided across global markets.
|
Founded Year | Domain | Location | |
|
Inhaled therapeutics for respiratory diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Skyepharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Skyepharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Skyepharma Comparisons
Competitors of Skyepharma
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Skyepharma
Frequently Asked Questions about Skyepharma
When was Skyepharma founded?
Skyepharma was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Where is Skyepharma located?
Skyepharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
What does Skyepharma do?
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs).
Who are Skyepharma's investors?
Skyepharma has 2 investors. Key investors include Barclays, and Phillips Medisize.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.